The Embleema HIVE bioinformatics platform expedites regulatory approvals for personalized medicine.
A comprehensive bioinformatics and regulatory analytics platform for all genomic and biomarker data. HIVE has been used by the FDA for regulatory decisions and research projects since 2013.
HIVE is the only software with the Authorization to Operate (ATO) for analyzing genomic data in the FDA regulatory review environment and has been used by the FDA for regulatory decisions since 2013.
By using HIVE and aligning to FDA bioinformatics standards and protocols, biopharma sponsors expedite their regulatory approvals by months.
Delayed phase 1 clinical trial by 6 months
Burned ~ $15,000,000 of costs
Lost up to ~ $75,000,000 of revenue
Lifted the FDA hold (accelerated approval by 4 months)
~ $12,000,000 of cost savings
~ $50,000,000 of future revenues added
The HIVE team is a co-author of the IEEE BioCompute standard, a framework for standardizing & sharing computations & analyses which eases the exchange of HTS workflows between the FDA, pharmaceutical companies, contract research organizations, providers & academic researchers. HIVE has published over 40 peer reviewed scientific articles.
Open APIs for third-party system integration
Extensive knowledgebases curated and shared in common with the FDA
BioCompute
Full provenance of data and analytics using BioSample & BioCompute accepted by the FDA
Comprehensive data standardization and harmonization
Sole platform with FDA authorization to operate (ATO) in a regulatory environment
NIST 800 compliant, FISMA-M compliant, HIPAA and GDPR-enabled
CFR21 Part 11
Federally–approved archival system
Supports long-term storage of scientific data data, analytics, and methods to interpret it
Comprehensive data standardization and harmonization
Peer-reviewed algorithms and pipelines used by the FDA
Interactive visualizations of terabytes of multi-omics data
Present your data in easily analyzable format
Life sciences align with the FDA on their genomic data management, analytics and submission to accelerate NDAs, BLAs and INDs.
Non-comprehensive (miss revirulent genomic mutations of the attenuated virus)
Time consuming
(~6 months)
Cost prohibitive
Raises ethical questions on level of animal testing
Comprehensive
Fast (1 week)
Analysis accepted by the FDA
Cut back on animal testing